EUCTR2022-002928-12-PL进行中（未招募）1 期
A Single-arm, Open-label, Multiple-dose, Phase 3 Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P47 in Patients with Moderate to Severe Active Rheumatoid Arthritis
CELLTRION, Inc.0 个研究点目标入组 30 人开始时间: 2022年11月4日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Each patient must meet all of the following criteria to be enrolled in this study:
- •1. Patient is male or female aged 18 to 70 years old, both inclusive.
- •2. Patient with a body weight of <100 kg.
- •3. Patient must be able and willing to self-administer SC injections.
- •4. Patient has had a diagnosis of RA according to the 2010 ACR/EULAR classification criteria
- •(Aletaha et al., 2010) for at least 24 weeks prior to the first administration of the study drug (Day 1).
- •5. Patient must have moderate to severe disease activity as defined by all of the following at Screening:
- •6 or more swollen joints (of 66 assessed)
- •6 or more tender joints (of 68 assessed)
- •either an ESR =28 mm/hour or a serum C-reactive protein (CRP) concentration =1.0 mg/dL
- •(=10 mg/L)
- •6. Patient who has been receiving oral or parenteral MTX for at least 12 weeks and who has been on a
- •stable dose and route of MTX between 10 to 25 mg/week for at least 8 weeks prior to the first administration of the study drug (Day 1).
- •7. Patient has adequate renal and hepatic function at Screening as defined by the following clinical
- •chemistry results:
- •Serum creatinine =1.5 × upper limit of normal (ULN) or an estimated creatinine clearance level
- •>50 mL/min (by Cockcroft-Gault formula) (SI [Système International d'Unités] units:
- •0.84 mL/s)
- •Serum alanine aminotransferase =2.0 × ULN
- •Serum aspartate aminotransferase =2.0 × ULN
- •Serum total bilirubin =1.5 × ULN
- •8. Patient has the following hematology laboratory test results at Screening:
- •Absolute neutrophil count =2,000/mm3 (2.0×103/µL)
- •Platelet count =100,000/mm3 (100.0×103/µL)
- •9. Patient and their partner of childbearing potential must agree to use following highly effective
- •method of contraception consistent with local regulations throughout the study and for 6 months
- •after the last dose of assigned treatment. A man or woman is of childbearing potential if, in the
- •opinion of the investigator, he or she is biologically capable of having children and is sexually active
- •(i.e., a man is fertile after puberty unless permanently sterile by bilateral orchidectomy or a woman
- •is fertile, following menarche and until becoming postmenopausal unless permanently sterile).
- •-Combined (estrogen and progestogen containing) or progestogen-only hormonal contraceptives
- •associated with inhibition of ovulation
- •- Intrauterine device or system
- •- True abstinence, when this is in line with the preferred and usual lifestyle of the patient.
- •Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods),
- •declaration of abstinence for the duration of exposure to investigational drug, and withdrawal are not acceptable methods of contraception.
- •- Double contraceptive methods (e.g., male condom in addition to use of hormonal or barrier method in female); for male patient with his female partner of childbearing potential only.
- •If patient or their partner has been surgically sterilized for less than 24 weeks prior to the date of
- •informed consent, they must agree to use any medically acceptable methods of contraception.
- •Postmenopausal females must have experienced their last menstrual period more than 1 year prior to
- •the date of informed consent without an alternative medical cause to be classified as not of
- •childbearing potential.
- •10. Patient (or legal guardian, if applicable) is informed of the full nature and purpose of the study, including possible risks and side effects, has the ability to cooperate with the investigator and is given ample
排除标准
- •1. Patient who has previously received investigational or licensed product; targeted synthetic DMARD(s) for the treatment of RA and/or an interleukin-6 (IL-6) inhibitor for any purposes.
- •2. Patient who has previously received more than 1 biologic agents approved for the treatment of RA.
- •3. Patient who has allergies to any of the excipients of study drug or any other murine and human proteins, or patient with a hypersensitivity to immunoglobulin products.
- •4. Patient who currently has, or has a history of, any of the following infections:
- •A known infection with hepatitis B or hepatitis C, or infection with human immunodeficiency virus (HIV). However, a patient with past hepatitis B virus is allowed if resolved.
- •Acute infection requiring oral antibiotics within 2 weeks prior to the first administration of the study drug (Day 1), or a serious infection associated with hospitalization and/or which required parenteral injection of antibiotics within 24 weeks prior to the first administration of the study drug (Day 1)
- •Recurrent herpes zoster or other chronic or recurrent infection within 6 weeks prior to the first administration of the study drug (Day 1)
- •Past or current granulomatous infections or other severe or chronic infections. However, a patient who has a past diagnosis with sufficient documentation of complete resolution of the infection can be enrolled in the study.
- •Patient has active tuberculosis, latent TB (defined as a positive result for interferon-? release assay [IGRA] with no active lesion in examination of chest X-ray without any sign or symptom of TB), a history of active TB , had close contact with a person with active TB or traveled to areas within a high incidence of TB within 8 weeks prior to study drug administration, or has plans to travel to an area with a high incidence of TB during the study period. If the result of IGRA is indeterminate at the screening, retest will be allowed only once during the screening period. If the repeated IGRA result is again indeterminate or positive, the patient will be excluded from the study. If the repeated IGRA result is negative, the patient can be included in the study.
- •5. Patient who has received or plans to receive any of the following prohibited medications or
- •Intra-articular corticosteroids within 4 weeks prior to the first administration of the study
- •drug (Day 1). A patient is permitted to receive either oral or parenteral glucocorticoids (=10 mg daily of prednisone/prednisolone or equivalent) and non-steroidal antiinflammatory drug, if they have received a stable dose for at least 4 weeks prior to the first administration of the study drug (Day 1) and the same dose must be maintained during the study period. In addition, a patient is permitted to receive low-potency topical, inhaled,otic, and ophthalmic glucocorticoid preparations provided, if the preparations are
- •administered per the instructions on the product label.
- •Conventional DMARDs, other than MTX, including hydroxychloroquine, chloroquine, or
- •sulfasalazine within 4 weeks prior to the first administration of the study drug (Day 1). A
- •patient who discontinued leflunomide and have had successful chelation with 8 g of
- •cholestyramine (3 times daily) for 11 days must wait 4 weeks after the last dose of
- •cholestyramine prior to the first administration of the study drug (Day 1). A patient who
- •discontinued leflunomide and did not have cholestyramine washout must wait 12 weeks
- •after the last dose of lef
研究者
相似试验
进行中（未招募）
1 期
Evaluating Usability of Subcutaneous Auto-injector of CT-P17 in Patients with Moderate to Severe Active Rheumatoid ArthritisModerate to Severe Active Rheumatoid ArthritisMedDRA version: 21.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2019-000660-25-PLCELLTRION, Inc.60
进行中（未招募）
1 期
A study to validate health outcomes of maribavir for the treatment of cytomegalovirus (CMV) infection in children and adolescents who have received transplantEUCTR2021-004279-15-DETakeda Development Center Americas, Inc.80
进行中（未招募）
1 期
A study to validate health outcomes of maribavir for the treatment of cytomegalovirus (CMV) infection in children and adolescents who have received transplantCytomegalovirus (CMV) infection in children and adolescents who have received a hematopoietic stem cell transplant (HSCT) or a solid organ transplant (SOT)MedDRA version: 20.0Level: LLTClassification code 10021829Term: Infection in solid organ transplant recipientsSystem Organ Class: 100000004862MedDRA version: 20.0Level: LLTClassification code 10021819Term: Infection in marrow transplant recipientsSystem Organ Class: 100000004862EUCTR2021-004279-15-FRTakeda Development Center Americas, Inc.80
进行中（未招募）
1 期
A study to validate health outcomes of maribavir for the treatment of cytomegalovirus (CMV) infection in children and adolescents who have received transplantEUCTR2021-004279-15-BETakeda Development Center Americas, Inc.80
进行中（未招募）
1 期
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Children and Teenage Transplant Recipients With CMV InfectioCytomegalovirus Infection in Hematopoietic Stem Cell or Solid Organ Transplant RecipientsEUCTR2021-004279-15-Outside-EU/EEATakeda Development Center Americas, Inc.